StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

IPCALAB — IPCA LABORATORIES LTD

Price History

Data as of 26 Jun 2026· via fincrux

How IPCALAB has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range90% of range

Trading about 28% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹1,269 low₹1,656 high
vs 50-day avg
+3.3%
vs 200-day avg
+10.9%
Beginner mode
Plain English, with everything explained

IPCALAB

NSE

IPCA LABORATORIES LTD

Healthcare / Pharma

₹1,618.30
0.00%
last close
0%
Quality Score
Looks high-qualityBig money steady

IPCA LABORATORIES LTD clears 3 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹38675.00 Cr
Price tag
33.5×
Money it earns
15.5%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.04goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 15.5%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 47.8%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What IPCALAB owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings7761,4401,152906295
Equity Capital2525252525
Reserves5,4505,8526,3236,8667,954
Total Assets7,4388,4478,6599,0719,776
Total Liabilities7,4388,4478,6599,0719,776

Borrowings trending down

Total borrowings are down about 62% over the last 5 years — the company has been reducing its reliance on debt.

Periodic Performance

Yearly net profit for IPCALAB — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹860 Cr
₹506 Cr
₹530 Cr
₹651 Cr
₹1,133 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹5,405 Crrev ₹5,775 Crrev ₹6,124 Crrev ₹6,635 Crrev ₹7,337 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about IPCALAB — observations, not recommendations.

Strengths

4
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Large professional investors have been holding steady or adding to their stake.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

1
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
10.6%-0.0 pp
DII· Domestic institutions
37.1%+1.3 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
  • LAURUSLABSLAURUS LABS LIMITED100
View the full sector